Renascience

Renascience FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Renascience (4889.T) as of Nov 19, 2026 is 96.69 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -156.17 % — a change of -161.91% (higher).

FCF Conversion

96.69 %

YoY

-161.91%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Renascience is 2026 96.69 % . FCF Conversion Rate (FCF/EBITDA) of Renascience was 2025 -156.17 % . It decreases by -161.91% higher compared to the previous year.

The Renascience FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
96.91 JPY
Jan 1, 2021
90.22 JPY
Jan 1, 2022
91.10 JPY
Jan 1, 2023
85.43 JPY
Jan 1, 2024
89.84 JPY
Jan 1, 2025
-156.17 JPY
Jan 1, 2026
96.69 JPY
The Renascience FCF Conversion history
YEARFCF ConversionYoY
96.69 %-161.91%
-156.17 %-273.83%
89.84 %+5.17%
85.43 %-6.22%
91.10 %+0.98%
90.22 %-6.91%
96.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

FCF Conversion Rate (FCF/EBITDA) of Renascience is 96.69 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Renascience changed from -156.17 % to 96.69 %, representing a -161.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Renascience since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Renascience with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Renascience

All Key Metrics — Renascience